Loading
A US National Cancer Institute network, led by Fred Hutch Cancer Center in Seattle, that tests new ways of screening for cancer. Its first study, Vanguard, is checking whether blood tests that look for many cancers at once can be studied properly in a large trial.
The NCI Division of Cancer Prevention describes the CSRN as a multi-centre effort, led by Fred Hutch Cancer Center, to examine the effectiveness of emerging technologies for cancer screening, with ACCESS hubs that enrol participants and coordinating centres. Its first study is the Vanguard Study, which will enrol up to 24,000 people, randomised to a control arm or to one of two multi-cancer detection test arms, to inform the design of a much larger randomised trial of whether the benefits of such tests outweigh the harms and whether they reduce deaths. The two assays selected, in NCI's alphabetical order, are the Avantect MCD Test (ClearNote Health) and the Shield MCD Test (Guardant Health), provided without cost to participants and not compared with each other. The NCI Moonshot page lists the creation of the CSRN and support for Vanguard among the Moonshot's accomplishments.
Shares The hardest cancers are found late and the tag research-funding.
Shares National Cancer Institute (NIH) and the tag research-funding.
Shares Overdiagnosis and false alarms and the tag research-funding.
Shares The hardest cancers are found late and the tag research-funding.
Shares The hardest cancers are found late and the tag research-funding.
Shares Overdiagnosis and false alarms and the tag research-funding.
Shares National Cancer Institute (NIH) and the tag research-funding.
Shares National Cancer Institute (NIH) and the tag research-funding.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/